# Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

Submission date	Recruitment status	Prospectively registered
30/09/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	Individual participant data
12/02/2018	Cancer	Record updated in last year

# Plain English summary of protocol

Not provided at time of registration

# Contact information

#### Type(s)

Scientific

#### Contact name

Mr Santbir Mehta

#### Contact details

University of Sheffield Urology Royal Hallamshire Hospital Sheffield United Kingdom S26 4SY +44 (0)788 956 9670/271 2154 sampimehta@aol.com

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

#### Scientific Title

Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

#### **Study objectives**

To identify any difference in relief of discomfort of prostate biopsy when using 1% or 2% lignocaine periprostatic nerve block

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Hospital

#### Study type(s)

Other

#### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

#### Health condition(s) or problem(s) studied

Prostate cancer

#### **Interventions**

Prospective randomised controlled trial comparing 1% and 2% lignocaine as a form of anaesthesia prior to prostate biopsy

#### Intervention Type

Drug

#### Phase

Not Applicable

# Drug/device/biological/vaccine name(s)

Lignocaine

#### Primary outcome measure

Difference on visual analogue scale (VAS)

#### Secondary outcome measures

Not provided at time of registration

#### Overall study start date

01/01/2004

#### Completion date

30/04/2004

# **Eligibility**

#### Key inclusion criteria

CaP (prostate cancer) patients

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Sex

Male

#### Target number of participants

Not provided at time of registration

#### Key exclusion criteria

Does not match inclusion criteria

#### Date of first enrolment

01/01/2004

#### Date of final enrolment

30/04/2004

## Locations

#### Countries of recruitment

England

**United Kingdom** 

Study participating centre University of Sheffield Sheffield United Kingdom S26 4SY

# Sponsor information

#### Organisation

Department of Health

#### Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

#### Sponsor type

Government

#### Website

http://www.dh.gov.uk/Home/fs/en

# Funder(s)

#### Funder type

Hospital/treatment centre

#### **Funder Name**

Sheffield Teaching Hospitals NHS Foundation Trust (UK)

# **Results and Publications**

### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration